Abstract:Serum amyloid A (SAA) is a highly conserved acute‐phase protein that plays roles in activating multiple pro‐inflammatory pathways during the acute inflammatory response and is commonly used as a biomarker of inflammation. It has been linked to beneficial roles in tissue repair through improved clearance of lipids and cholesterol from sites of damage. In patients with chronic inflammatory diseases, elevated levels of SAA may contribute to increased severity of the underlying condition. The majority of circulating SAA is bound to lipoproteins, primarily high‐density lipoprotein (HDL). Interaction with HDL not only stabilizes SAA but also alters its functional properties, likely through altered accessibility of protein–protein interaction sites on SAA. While high‐resolution structures for lipid‐free, or apo‐, forms of SAA have been reported, their relationship with the HDL‐bound form of the protein, and with other possible mechanisms of SAA binding to lipids, has not been established. Here, we have used multiple biophysical techniques, including SAXS, TEM, SEC‐MALS, native gel electrophoresis, glutaraldehyde crosslinking, and trypsin digestion to characterize the lipid‐free and lipid‐bound forms of SAA. The SAXS and TEM data show the presence of soluble octamers of SAA with structural similarity to the ring‐like structures reported for lipid‐free ApoA‐I. These SAA octamers represent a previously uncharacterized structure for lipid‐free SAA and are capable of scaffolding lipid nanodiscs with similar morphology to those formed by ApoA‐I. The SAA–lipid nanodiscs contain four SAA molecules and have similar exterior dimensions as the lipid‐free SAA octamer, suggesting that relatively few conformational rearrangements may be required to allow SAA interactions with lipid‐containing particles such as HDL. This study suggests a new model for SAA–lipid interactions and provides new insight into how SAA might stabilize protein‐lipid nanodiscs or even replace ApoA‐I as a scaffold for HDL particles during inflammation.

Acute-serum amyloid A and A-SAA-derived peptides as formyl peptide receptor (FPR) 2 ligands

Serum Amyloid A1 (SAA1) Revisited: Restricted Leukocyte-Activating Properties of Homogeneous SAA1

A Seven-transmembrane, G Protein–coupled Receptor, FPRL1, Mediates the Chemotactic Activity of Serum Amyloid A for Human Phagocytic Cells

Emerging Functions of Serum Amyloid A in Inflammation

COOH-terminal SAA1 peptides fail to induce chemokines but synergize with CXCL8 and CCL3 to recruit leukocytes via FPR2.

Serum amyloid A1: Structure, function and gene polymorphism

Acute phase reactant serum amyloid A in inflammation and other diseases.

Adenoviral Expression of Murine Serum Amyloid A Proteins to Study Amyloid Fibrillogenesis

Serum Amyloid A Induces M2 Macrophage-Specific Genes Expression and Promotes Efferocytosis of Apoptotic Neutrophils (P5072)

Structural studies of a serum amyloid A octamer that is primed to scaffold lipid nanodiscs

Serum amyloid protein A in inflammatory bowel disease: from bench to bedside

Serum Amyloid A Exhibits Ph Dependent Antibacterial Action and Contributes to Host Defense Against Staphylococcus Aureus Cutaneous Infection.

Serum amyloid A stimulates lipoprotein-associated phospholipase A2expression invitro and invivo

Serum Amyloid A Activates Peroxisome Proliferator-Activated Receptor Γ Through Extracellularly Regulated Kinase 1/2 and COX-2 Expression in Hepatocytes.

The Inhibition of Serum Amyloid A Protein Aggregation by a Five-Residue Peptidomimetic: Structural and Morphological Insights

Serum amyloid A stimulates vascular endothelial growth factor receptor 2 expression and angiogenesis

Ex Vivo and In Vitro Effect of Serum Amyloid A in the Induction of Macrophage M2 Markers and Efferocytosis of Apoptotic Neutrophils

Amyloidogenesis. One serum amyloid A isotype is selectively removed from the circulation

Structural Determinants in the Staphylococcus aureus-Derived Phenol-Soluble Modulin α2 Peptide Required for Neutrophil Formyl Peptide Receptor Activation

Functional activation of the formyl peptide receptor by a new endogenous ligand in human lung A549 cells